As the world's largest independent blood and plasma donation center operator, ImmunoTek invites the Morristown community to visit the facility to learn more about plasma donations and how they can positively impact others.
By removing the red and white blood cells from the blood, what remains is the golden liquid called plasma.
Blood-plasma helps create medicines and plasma-based therapies that treat patients with various diseases and disorders, including shock and burn patients, bleeding disorders, transplant patients, those suffering from autoimmune diseases, and many others.
Scientists cannot synthesize blood-plasma, so centers like the new ImmunoTek Plasma in Morristown are vital to keeping up with the worldwide demand for plasma.
The United States provides 2/3 of the world's plasma, and demand increases by 6% - 8% yearly.
To be eligible to donate plasma, in-house medical professionals conduct a medical screening, medical history review, and physical exam. Donating plasma is much like making a blood donation.
A safe, sterile, automated process called plasmapheresis separates plasma from the blood and returns the remaining red blood cells to the donor. Donors can give plasma up to twice a week.
ImmunoTek Plasma's new Morristown location is at 3004 W Andrew Johnson Hwy and will operate Tuesday – Saturday.
Walk-in donors are welcome for their first donation; subsequent donations are only by appointment.
Operated by ImmunoTek Bio Centers LLC, ImmunoTek Plasma provides a chance for plasma donors to positively impact the lives of patients who rely on plasma-based therapies while being compensated for their time.
ImmunoTek Bio Centers is the world's largest independent plasma collection center operator.
Akeso's Ebdarokimab approved in China for moderate-to-severe plaque psoriasis
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Organon acquires US rights to TOFIDENCE from Biogen
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
Hemogenyx's CAR-T therapy passes initial safety tests in Phase I trial
Syneron Bio to collaborate with AstraZeneca
Everest Medicines' EVM14 IND application receives US FDA approval